Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

Mark P Chao
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA

Abstract: Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin’s lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nevertheless, there are multiple emerging classes of targeted therapies for relapsed/refractory disease, including monoclonal antibodies, antibody–drug conjugates, radioimmunotherapy, small-molecule inhibitors of cell-growth pathways, and novel chemotherapy agents. This review will discuss treatment challenges of NHL, current available salvage regimens for relapsed/refractory NHL, and the safety and efficacy of novel emerging therapies.

Keywords: non-Hodgkin’s lymphoma, relapsed/refractory disease, novel therapies

Introduction to non-Hodgkin’s lymphoma: treatment challenges

Non-Hodgkin’s lymphoma (NHL) is the fifth most common cancer in the US, where its incidence has been increasing over the last three decades.1 NHL comprises a group of clinically and biologically diverse diseases, which range from indolent to aggressive clinical courses. Indolent subtypes include but are not limited to follicular lymphoma (FL), marginal zone lymphoma (MZL), cutaneous T-cell lymphoma (CTCL), small-cell lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), and lymphoblastic lymphoma, which make up 30% of all NHL cases in the US. Aggressive subtypes include diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), and mantle-cell lymphoma (MCL). Among aggressive subtypes of NHL, DLBCL is the most prevalent, and represents approximately 30% of all NHL diagnoses in adults.2 Despite treatment advances in the last three decades with the use of combination immunotherapy, a significant fraction of patients relapse or are refractory to these treatments. While many treatment difficulties exist in NHL, rituximab resistance and refractory/relapsed disease represent current and emerging challenges.

Rituximab resistance

Within the last two decades, the development and use of the monoclonal antibody (mAb) rituximab has dramatically improved the prognosis of NHL patients, and has been the standard of care in front-line treatment regimens. Standard front-line chemotherapy includes rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP), with expected 5-year and 10-year overall survival (OS) rates of 58% and 43.5%, respectively.\textsuperscript{7} Rituximab is a chimeric \textit{mAb} targeting CD20, a cell-surface marker present on B-lineage cells and consequently expressed on many B-cell lymphoma subtypes. Multiple lines of evidence indicate that rituximab acts in part by engaging Fc receptors on immune effector cells, such as natural killer cells and macrophages, and stimulates such effector functions as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.\textsuperscript{8} While therapeutic outcomes have dramatically improved in the post-rituximab era, there is increasing evidence of rituximab resistance. Clinical resistance to rituximab is generally defined as a lack of response to a rituximab-containing treatment regimen or clinical progression after 6 months of such a regimen. Diminished response rates to rituximab in patients with prior rituximab treatments have been observed in multiple NHL subtypes. In patients with relapsed FL or low-grade NHL who had previously received single agent rituximab, only 40% of patients responded with rituximab retreatment.\textsuperscript{3} In one study of relapsed/refractory DLBCL, patients with and without prior rituximab exposure were treated with salvage chemotherapy followed by stem-cell transplantation. Complete response (CR) rates after salvage chemotherapy were lower in patients receiving prior rituximab compared to naïve patients (29% vs 44%), although this difference was not significant in multivariate analysis.\textsuperscript{4} However, patients with prior rituximab treatment had significantly worse progression-free survival (PFS) than patients who were rituximab-naïve (17% vs 57%). Prior rituximab treatment was an independent adverse prognostic factor for survival. In the Collaborative Trial in Relapsed Aggressive Lymphoma study, relapsed/refractory DLBCL patients who were previously treated with rituximab also had a worse outcome when retreated with rituximab-containing therapies.\textsuperscript{7} Poorer outcomes were specifically seen in previously treated rituximab patients who relapsed or progressed during the first year. These data and others highlight the clinical concern that salvage regimens for relapsed/refractory patients may not be as effective in the era of rituximab usage in front-line regimens. Thus, overcoming rituximab resistance has been a major focus of recent therapeutic development. Several mechanisms of rituximab resistance have been postulated. These include resistance in antibody effector mechanisms (ADCC, CDC, and induction of apoptosis), Fc-receptor polymorphisms, downregulation or loss of CD20 expression, and altered antibody pharmacokinetics.\textsuperscript{9} To address these issues, one major treatment strategy has been the development of novel anti-CD20 antibodies that more effectively engage immune effectors and bind CD20 with higher avidity. Several of these next-generation anti-CD20 antibodies are in late-stage clinical development. Other nonantibody therapies have also been demonstrated to enhance CD20 expression changes and/or sensitize tumor cells to rituximab in the hope of overcoming rituximab resistance. Through potential epigenetic regulation of CD20 expression, histone deacetylase inhibitors (HDACs) have been shown to increase CD20 expression and enhance rituximab cytotoxicity in vitro.\textsuperscript{9} Other therapeutic agents, including temsirolimus, bortezomib, and Bcl-2 inhibitors, have also been shown to sensitize lymphoma cells to rituximab in preclinical studies. A more extensive review of these agents and anti-CD20 antibodies will be undertaken later.

### Relapsed and refractory NHL

Response rates to conventional chemotherapy are generally greater than 50%; however, most patients eventually relapse. A brief survey of treatment options for refractory DLBCL, PTCL, CLL, FL, and MCL will be discussed.

While no standard of care exists for salvage regimens, a number of regimens have been studied as options for salvage therapy (Figure 1). For DLBCL, a common salvage regimen includes ifosfamide, carboplatin, and etoposide (ICE), which has produced an overall response rate (ORR) of 66%.\textsuperscript{12} With the addition of rituximab, CR rates improved from 24% to 53% without increased toxicity.\textsuperscript{11} Rituximab, etoposide, methylprednisone, cytarabine, and cisplatin (R-ESHAP) achieved an ORR of 73%, representing another common salvage regimen.\textsuperscript{6} In PTCL, treatment options include single- and multiagent chemotherapy, with the exception of rituximab, given the lack of CD20 expression on T-cell lymphomas. Relapse rates are high due to low efficacy of first-line regimens and a relative dearth of large-scale trials for refractory PTCL. Thus, the discovery of novel treatments for PTCL is a high priority. In CLL, the majority of refractory patients are unresponsive to fludarabine, a cornerstone of first-line therapy. In the era of single-agent fludarabine, up to 37% of patients were found to be fludarabine-refractory, which has decreased to less than 10% with the addition of rituximab-containing front-line therapies.\textsuperscript{12,13} Genetic abnormalities, including deletion in the short arm of chromosome 17 (del[17p]) and in the long arm of chromosome 11 (del[11q]), are associated with poor response to fludarabine and other agents.\textsuperscript{14,15} Salvage regimens are stratified based on genetic subtype, and include \textit{mAbs} (alemtuzumab and ofatumumab) and rituximab-containing combination chemotherapies. Salvage options for FL include rituximab alone or in combination with alkylating agents, radioimmunotherapy, and other agents not used in first-line therapy. For patients who respond to salvage immunochemotherapy, maintenance therapy with rituximab has been shown to reduce...
the risk of progression and mortality. For MCL, rituximab in combination with chemotherapies, including bendamustine and fludarabine, have been utilized. Newer agents, including the proteosome inhibitor bortezomib and the thalidomide derivative lenalidomide, have been increasingly incorporated into second-line regimens.

Several factors are considered when selecting a salvage regimen. For aggressive lymphoma subtypes, the decision on therapy is based on whether patients are candidate for stem-cell transplants. Those patients that are not candidates (due to age, poor performance status, or significant comorbidities) undergo chemotherapy with a goal of minimizing toxicity. However, prognosis is poor among these patients, with expected survival of less than 1 year. In DLBCL, autologous hematopoietic stem-cell transplant (auto-SCT) has become the standard of care for patients in first relapse. Based on the landmark Parma trial, relapsed NHL patients were randomized to either conventional chemotherapy or high-dose chemotherapy followed by auto-SCT, with a significantly more favorable response and event-free survival rate in the auto-SCT group. The use of allogeneic hematopoietic SCT (allo-SCT) compared to auto-SCT has been generally limited.

While allo-SCT has led to lower relapse rates compared to auto-SCT, the myeloablative pretransplant regimen has led to increased treatment-related fatalities. Treatment-related mortality can reach up to 25% with allogeneic transplantation, thus precluding its use in many patients. While auto-SCT has a clear role in DLBCL, transplantation is not as clear for other NHL subtypes. Prior prospective studies have shown mixed benefit for extending survival in relapsed FL. For CLL, SCT has been used in fludarabine-refractory patients. In contrast to other NHL subtypes, allo-SCT is used for CLL, as auto-SCT has not been shown to have curative potential. Reduced-intensity conditioning regimens for allo-SCT are currently used, given high treatment-related mortality rates observed in myeloablative conditioning. Cytoreduction with salvage therapy followed by consolidation allo-SCT is often the goal (Figure 1). The role of transplantation is not as well described in other less common NHL subtypes, including T-cell lymphomas and MCL, mainly due to difficulty in patient accrual for large prospective trials. Given the promising efficacy of emerging novel antibody and other targeted therapies for these NHL subtypes, it is possible that stem-cell transplantation will play a more limited role in the future.
Novel and emerging therapies for NHL

Over the last decade, a multitude of therapies have entered clinical development for NHL. These therapies range from novel mAbs (including next-generation anti-CD20 mAbs), antibody–drug conjugates (ADCs), radioimmunotherapy, small-molecule inhibitors targeting cell survival and growth pathways, and novel chemotherapies (Figure 2). Many of these therapies have shown considerable promise, providing significant response rates in heavily pretreated NHL patients. Therapeutic agents in early to late-phase clinical trials will be reviewed here.

Monoclonal antibody therapies

Anti-CD20 antibodies

With the emergence of rituximab resistance, next-generation anti-CD20 mAbs have been developed to augment effector-function potency and increase CD20 binding avidity. Second- and third-generation anti-CD20 antibodies have been developed and are in clinical trials. Second-generation antibodies all possess fully human immunoglobulin G to reduce immunogenicity, and include ocrelizumab, veltuzumab, and ofatumumab. Third-generation antibodies are humanized, and have an engineered Fc region to improve therapeutic effector functions. These include AME-133v, GA101, TRU-015, PRO13192, and others. Clinical data on late-stage second-generation anti-CD20 antibodies will be reviewed here (Table 1). Anti-CD20 antibodies in early phase clinical development, including third-generation antibodies, are reviewed elsewhere.23,24

Ofatumumab

Ofatumumab is the first humanized anti-CD20 mAb approved in the US and Europe. It is a second-generation anti-CD20 mAb that binds both small and large loops of the CD20 surface epitope, whereas rituximab binds to the large loop alone.25 Unique features of ofatumumab include high CD20 epitope sensitivity, slow off rate, and high CDC activity.26 In vitro, ofatumumab induces stronger CDC in cell lines that are rituximab-resistant.27 Ofatumumab was first evaluated as a monotherapy in a phase I/II trial on heavily pretreated patients with relapsed/refractory CLL. Ofatumumab was very well tolerated, with an ORR of 50% at the highest dose administered.28 A subsequent landmark phase II trial of ofatumumab in fludarabine and alemtuzumab-refractory patients demonstrated an ORR of 47%–58% in both groups, with the most common adverse events being...
Table 1 Emerging antibody therapies in non-Hodgkin’s lymphoma

<table>
<thead>
<tr>
<th>Monoclonal Ab</th>
<th>Ab type</th>
<th>Phase</th>
<th>Patients</th>
<th>Disease</th>
<th>Regimen</th>
<th>Response</th>
<th>Ref</th>
<th>Current use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-CD20 antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocrelizumab</td>
<td>Humanized, IgG₁</td>
<td>I/II</td>
<td>47</td>
<td>R/R FL</td>
<td>Ocrelizumab</td>
<td>ORR 38%, PFS 11.4 mo</td>
<td>33</td>
<td>Phase III</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>Humanized, IgG₁</td>
<td>II</td>
<td>138</td>
<td>FA-ref, BF-ref CLL¹</td>
<td>Ofatumumab</td>
<td>ORR: FA-ref 58%, BF-ref 47%</td>
<td>29</td>
<td>FDA-/EMA-approved for R/R CLL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>61</td>
<td>Untreated CLL</td>
<td>O-FC</td>
<td>ORR 75%, CR 41%</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>116</td>
<td>Rituximab R/R FL</td>
<td>Ofatumumab</td>
<td>ORR 11%</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>59</td>
<td>Untreated FL</td>
<td>O-CHOP</td>
<td>ORR: FL 79%, CR 41%</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Veltuzumab</td>
<td>Humanized, IgG₁₂₀</td>
<td>I/II</td>
<td>82</td>
<td>R/R NHL</td>
<td>Veltuzumab</td>
<td>ORR 41%, CR 21%</td>
<td>35</td>
<td>Early phase</td>
</tr>
<tr>
<td>Other antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinatumomab</td>
<td>Anti-CD3/CD19 Bispecific</td>
<td>I</td>
<td>62</td>
<td>R/R NHL</td>
<td>Blinatumomab</td>
<td>ORR 82%, all subtypes</td>
<td>53</td>
<td>Phase II</td>
</tr>
<tr>
<td>Epratuzumab</td>
<td>Humanized, IgG₁</td>
<td>II</td>
<td>63</td>
<td>R/R NHL</td>
<td>E-R</td>
<td>ORR 47%, all subtypes, 64% = FL, DLBCL = 47%</td>
<td>38</td>
<td>Phase III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>107</td>
<td>Untreated DLBCL</td>
<td>ER-ChOP</td>
<td>ORR 96%, CR 74%, OS (3-yr) 80%</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>Galiximab</td>
<td>Chimerized, IgG₁</td>
<td>I/II</td>
<td>35</td>
<td>R/R FL</td>
<td>Galiximab</td>
<td>ORR 11%, stable disease 34%</td>
<td>41</td>
<td>Phase III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>61</td>
<td>Untreated FL</td>
<td>Galiximab-R</td>
<td>ORR 72%, CR 48%</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Mogamulizumab</td>
<td>Humanized, IgG₁</td>
<td>II</td>
<td>27</td>
<td>CCR4⁺ ATL</td>
<td>Mogamulizumab</td>
<td>ORR 50%</td>
<td>45</td>
<td>Phase II, approved in Japan for ATL</td>
</tr>
<tr>
<td>Antibody–drug conjugates</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brentuximab</td>
<td>Anti-CD30, chimeric</td>
<td>II</td>
<td>58</td>
<td>R/R CD30⁺ ALCL</td>
<td>Brentuximab vedotin</td>
<td>ORR 86%, CR 57%</td>
<td>52</td>
<td>2 FDA-approved for R/R ALCL</td>
</tr>
<tr>
<td>Vedotin</td>
<td>MMAE-conjugated</td>
<td>II</td>
<td>58</td>
<td>R/R CD30⁺ ALCL</td>
<td>Brentuximab vedotin</td>
<td>ORR 86%, CR 57%</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Inotuzumab</td>
<td>Anti-CD22, humanized</td>
<td>I</td>
<td>79</td>
<td>R/R FL, DLBCL</td>
<td>Inotuzumab-Ozo</td>
<td>ORR: FL 68%, DLBCL 15%</td>
<td>46</td>
<td>Phase III</td>
</tr>
<tr>
<td>Ozogamicin</td>
<td>IgG₂, calicheamicin-conjugated</td>
<td>I/II</td>
<td>61</td>
<td>R/R FL, DLBCL</td>
<td>Inotuzumab-Ozo-R</td>
<td>ORR: FL 88%, DLBCL 71%</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Radioimmunotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹³¹I-tositumomab</td>
<td>anti-CD20 mouse IgG₂a, ¹³¹I-labeled</td>
<td>I/II²</td>
<td>250</td>
<td>R/R low grade,</td>
<td>¹³¹I-tositumomab transformed NHL</td>
<td>ORR 47–68%, CR 20%–38%</td>
<td>55</td>
<td>FDA-approved for R/R FL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>532</td>
<td>Untreated FL</td>
<td>R-CHOP vs CHOP + ¹³¹I-tositumomab</td>
<td>2-yr PFS: R-CHOP 76%, CHOP + ¹³¹I-tositumomab 80%</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>⁹⁰Y-ibritumomab</td>
<td>anti-CD20 mouse IgG₁, ⁹⁰Y-labeled</td>
<td>II</td>
<td>143</td>
<td>R/R FL</td>
<td>⁹⁰Y-ibritumomab vs R ⁹⁰Y-ibritumomab vs R</td>
<td>ORR: ⁹⁰Y-ibritumomab 80%, R = 56%</td>
<td>57</td>
<td>FDA-approved for untreated FL</td>
</tr>
<tr>
<td>Tiuxetan</td>
<td>⁹⁰Yttrium-conjugated</td>
<td>II/naive</td>
<td>143</td>
<td>R/R FL</td>
<td>(R-naive)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: ¹FA-ref, fludarabine/alemtuzumab-refractory; BF-ref, fludarabine-refractory with bulky lymphadenopathy (>5 cm); ²Integrated efficacy analysis of five clinical trials resulting in FDA approval of ¹³¹I-tositumomab; clinical trial data are presented for select antibody-based therapies. ³Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; E, epratuzumab; O-FC, ofatumumab + fludarabine/cyclophosphamide; O-CHOP, ofatumumab + cyclophosphamide, doxorubicin, vincristine, prednisone; R, rituximab; MMAE, monomethyl auristatin E; R/R, relapsed/refractory; ORR, overall response rate; CR, complete remission; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma; ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma.
grade 1–2 infections or infusion reactions.29 Based on these results, the FDA approved ofatumumab for the treatment of CLL patients refractory to fludarabine and alemtuzumab. Ofatumumab has also been evaluated in combination with front-line chemotherapy for patients with untreated CLL.30 Patients received ofatumumab in combination with fludarabine and cyclophosphamide, yielding an ORR and CR across all patients of 75% and 41%, respectively. Ofatumumab has also been studied as a monotherapy in FL. While ofatumumab was well tolerated in the initial phase I/II trial, a subsequent phase II trial was conducted in rituximab-refractory patients and demonstrated a relatively poor response rate of 11%.31 This observation suggested that ofatumumab might be more effective in a combination strategy in refractory FL. Indeed, in untreated FL patients, ofatumumab in combination with CHOP demonstrated an ORR of greater than 90% with a CR rate over 75%.32 Combination therapy with ofatumumab is also being studied in late-phase trials for FL and DLBCL, with hopes of gaining FDA approval for these subtypes.

**Ocrelizumab**

Ocrelizumab is a second-generation anti-CD20 antibody that differs from rituximab at several positions within the complementary-determining regions of the light- and heavy-chain variable regions, leading to increased affinity for the FcγRIIa receptor and enhanced ADCC.33 Ocrelizumab has been evaluated in a phase I/II study in relapsed/refractory FL patients that received prior rituximab therapy.34 Treatment was well tolerated, with grade 3/4 toxicities occurring in only 9% of patients and an ORR of 38%. While initial studies are encouraging, its clinical development for autoimmune diseases (an alternative indication) was suspended after excess deaths due to opportunistic infections, which may cause concern in future lymphoma studies.

**Veltuzumab**

Veltuzumab is a second-generation anti-CD20 antibody constructed on the framework regions of the anti-CD22 antibody epratuzumab, with complementary determining regions identical to rituximab, with the exception of a single amino acid chain substitution. In vitro, ADCC efficacy is similar to rituximab; however, veltuzumab has been reported to possess slower off rates and increased CDC.34 Veltuzumab was evaluated in a phase I/II study of relapsed/refractory NHL patients.35 ORR across all subtypes was 41%, ranging from 43% to 83% in DLBCL and MZL patients, respectively. Therapy was well tolerated, with no grade 3/4 adverse events. Additional early phase trials are ongoing.

**Other monoclonal antibodies**

**Epratuzumab**

Epratuzumab is a humanized anti-CD22 antibody that has been clinically studied in indolent and aggressive NHL. CD22 is a cell-surface antigen expressed on mature B lymphocytes and regulates B-cell function and survival. CD22 expression has been observed in 60%–80% of B-cell malignancies and over 90% in FL and DLBCL.36 Epratuzumab has also been investigated in combination-therapy strategies, most notably with rituximab. Initial phase I data demonstrated that this combination is well tolerated.37 A phase II trial of combination therapy with rituximab and epratuzumab in relapsed/refractory NHL patients (23% receiving prior rituximab therapy) demonstrated favorable responses (ORR of 47% and CR of 22%), with the best responses seen in FL and DLBCL (Table 1).38 Epratuzumab and rituximab have also been evaluated in front-line therapy. When these two antibodies were combined with CHOP chemotherapy in untreated DLBCL patients, ORR was 96%, with a CR of 72% and 1-year PFS of 82%. Toxicity was similar to standard R-CHOP. These results suggest that epratuzumab with R-CHOP may be a promising front-line therapy employing combination antibodies. Based on these data, phase III trials have been initiated.

**Galiximab**

Galiximab is a chimeric anti-CD80 mAb initially evaluated in psoriasis in phase I/II trials, where it was found to have minimal side effects.39 CD80 is a protein found on activated B cells that provides a costimulatory signal necessary for T-cell activation. It is constitutively expressed in most B-cell lymphomas.40 The initial phase I/II study of galiximab as a single agent was initiated in relapsed/refractory FL, with an ORR of 11% (Table 1).41 Sixty percent of patients experienced adverse events related to galiximab, but most were low-grade toxicities of fatigue, nausea, and headache. Hematologic toxicities were rare. Galiximab in combination with rituximab has also been evaluated as first-line treatment for FL in the Cancer and Leukemia Group B’s study 50402.42 Untreated FL patients received eight cycles of galiximab and rituximab that was well tolerated, with an ORR of 71% with 48% of patients achieving CR or unconfirmed CR. Phase III studies are ongoing to evaluate galiximab in combination with rituximab for FL.

**Mogamulizumab**

Mogamulizumab is a humanized antibody targeting the chemokine receptor CCR4. CCR4 is a transmembrane receptor selectively expressed on T-helper 2 and regulatory T cells that is expressed in 90% of patients with adult T-cell...
leukemia/lymphoma (ATL). In ATL, CCR4 expression was associated with increased skin infiltration and worse outcomes. Given the relatively few therapies available for relapsed/refractory ATL, CCR4 inhibition has emerged as a promising agent. Mogamulizumab recognizes the N-terminal region of human CCR4 and is defucosylated to enhance ADCC. Mogamulizumab was first investigated in CCR4-positive relapsed PTCL (including ATL), demonstrating no dose-limiting toxicities and an ORR of 31% (Table 1). A subsequent phase II trial of mogamulizumab was conducted in CCR4-positive relapsed ATL. ORR was 50%, with 100% response rate in the blood, 63% in the skin, and 25% for nodal/extranodal lesions. The most common adverse events were infusion reactions and skin eruptions. However, several cases of Stevens–Johnson syndrome have been reported, with further trials needed to evaluate for safety and efficacy. Nevertheless, mogamulizumab received regulatory approval for use in ATL in Japan in 2012. Clinical trials are ongoing for evaluation of approval in the US and Europe.

Antibody–drug conjugates
ADCs consist of a monoclonal antibody conjugated to a cytotoxic agent, whereby the mechanism of activity occurs by antigen–antibody binding and subsequent internalization of the cytotoxic drug. Drug conjugates not only enhance therapeutic efficacy of the original antibody but also do so with limited side effects and a wider therapeutic window, given tumor antigen-specific targeting.

Inotuzumab ozogamicin
Inotuzumab ozogamicin (CMC-544) is a human anti-CD22 immunoglobulin G4 antibody conjugated to the antitumor antibiotic calicheamicin, and is the most studied ADC in NHL. Because CD22 undergoes constitutive endocytosis, it is a well-suited target for intracellular toxin delivery. Given the relatively benign toxicity profile and promising tumor efficacy of the “naked” anti-CD22 epratuzumab, an ADC to CD22 was developed. In the first-in-human study, inotuzumab ozogamicin was administered to previously treated FL and DLBCL patients, and achieved an ORR of 39% (68% in FL and 15% in DLBCL) (Table 1). The combination of inotuzumab ozogamicin and rituximab was evaluated in phase I/II trials in relapsed/refractory FL or DLBCL, with a preliminary ORR reported of 88% for FL and 71% for DLBCL in the maximal-tolerable-dose cohort. However, response to prior therapy appears to be a major prognostic factor, as rituximab-refractory patients had ORR rates less than 20%. The most common treatment toxicities of inotuzumab ozogamicin observed in early trials were thrombocytopenia, neutropenia, and leukopenias. Based on these early studies, phase III trials are under way.

Brentuximab vedotin
CD30 is a cell-membrane receptor involved in nuclear factor-kB signaling and cell survival, and is widely expressed on Hodgkin’s and anaplastic large cell lymphoma (ALCL) cells. Therapeutic antibodies targeting CD30 have been developed, and while demonstrating impressive preclinical activity in xenograft mouse models, early clinical trials in HL and ALCL have shown only modest efficacy. In addition, dose-limiting pulmonary toxicity has been observed when combined with other chemotherapies. In contrast to the naked anti-CD30 antibody, the ADC brentuximab vedotin (SGN-35), which conjugates anti-CD30 antibody to the antimitotubule agent monomethyl auristatin E (MMAE), has shown significant activity in HL and ALCL. Anti-tumor efficacy of brentuximab vedotin stems from both cellular internalization of MMAE and release of free MMAE by tumor cells to surrounding cells. Clinical studies were first initiated in HL, leading to FDA approval for both HL and ALCL. Data on HL are reviewed elsewhere. Accelerated approval for ALCL was based on a multicenter trial treating CD30-positive systemic ALCL patients with brentuximab vedotin who had previously received front-line multiagent chemotherapy. ORR was 86%, with a CR rate of 57% and median duration response of 13.2 months (Table 1). Serious adverse events were reported in 31% of patients, of which peripheral neuropathy and abdominal pain were the most common. Recently, several cases of progressive multifocal leukoencephalopathy have been reported with brentuximab vedotin use, and while rare, these observations have led to an FDA boxed warning. Caution must also be made when combining brentuximab vedotin with other chemotherapies leading to increased pulmonary toxicity, including bleomycin.

Bispecific antibodies
Bispecific antibodies consist of an antibody composed of fragments of two monoclonal antibodies that bind separate antigens. Bispecific antibodies have distinct advantages over traditional mAbs, including increased tumor-targeting specificity through binding of two tumor-specific antigens and enhanced cytotoxic efficacy by engagement of multiple effector mechanisms. While several bispecific antibodies have been engineered for anticancer therapy for NHL, only one has proceeded through significant clinical trials: blinatumomab. Blinatumomab is a bispecific antibody targeting CD19 (a
B-cell marker) and CD3 (a T-cell engager) and belongs to the class of bispecific T-cell engager antibodies whereby tumor antibody-antigen targeting is linked to recruitment of T-cell activity. The first of its class utilized in NHL, blinatumomab targets CD19, which is widely expressed across all NHL subtypes and important for proliferation and survival of B cells. Targeting of CD19-expressing tumor cells is linked to recruitment and activation of cytotoxic T cells through simultaneous ligation of CD3 on the T-cell receptor, leading to T-cell-mediated tumor lysis. Blinatumomab has been clinically studied in both NHL and acute lymphoblastic leukemia. The first phase I study of 62 NHL patients treated with the recommended dose of blinatumomab demonstrated an ORR of 82% across NHL subtypes, with over 60% of responders maintaining durable response up to 3 years out from therapy (Table 1). The most significant adverse events reported were reversible central nervous system toxicities (including encephalopathy, tremor, and aphasia), which has led to discontinuation of the study drug in over 20% of patients. The mechanism of central nervous system-related events is currently not yet understood. Currently, phase II trials have been initiated in NHL patients. Multiple other bispecific antibodies are undergoing clinical investigation, including 4G7XH22 (anti-CD19/CD30), Bi20 (anti-CD20/CD3), and anti-CD20/CD22 antibodies.

Radioimmunotherapy

As another therapeutic application of antibodies, radioimmunotherapy employs mAb or mAb-derived vectors that are chemically conjugated to radioactive isotopes for tumor targeting and delivery. Radioisotope-conjugated antibodies have a key theoretical advantage compared to ADCs and other mAb therapies in that tumor cells not bound by mAb (due to low or negative target-antigen expression) can still be eliminated by cytotoxic effects of the surrounding radiation field. For NHL, the FDA has approved two radioimmunoconjugates: 131I-tositumomab (Bexxar) and 90Y-ibritumomab tiuxetan, both of which target the CD20 antigen. In 2003, the FDA approved 131I-tositumomab for the treatment of relapsed or refractory FL. In 2009, 90Y-ibritumomab tiuxetan was approved as a front-line consolidation treatment after induction chemotherapy in FL.

Both 131I-tositumomab and 90Y-ibritumomab tiuxetan have been extensively studied, and demonstrated high response rates and durable remissions within heavily pretreated populations, with predictable and manageable toxicity. An integrated analysis of five clinical trials on heavily pretreated indolent lymphoma patients treated with 131I-tositumomab demonstrated response rates between 47% and 68% and CR rates between 20% and 38% (Table 1). Patients who achieved CR had response durations that lasted years, with median duration not achieved at 5 years. Similar durable response rates for patients with relapsed/refractory FL or DLBCL have also been observed with 90Y-ibritumomab tiuxetan, with median duration of response over 3 years in patients who responded to treatment. Both of these drug conjugates have also been evaluated as first-line treatment for FL and other indolent NHL as well as consolidation therapy after initial chemotherapy, with high ORR and CR rates. A recent phase III trial randomizing six cycles of R-CHOP vs CHOP followed by 131I-tositumomab demonstrated high rates of PFS, but no difference in PFS or OS between the two groups. Multiple phase I/II trials have also been initiated to evaluate both radioisotope conjugates with other chemotherapeutic regimens.

While both radioisotope-conjugated antibodies have shown considerable efficacy, do these drugs have acceptable toxicities given the use of radioisotopes? In early and late-phase trials, safety profiles have been favorable, with reversible hematologic effects as the primary toxicity observed. In addition, these antibody conjugates are chimeric antibodies, raising theoretical concern for increased antibody immunogenicity. Nevertheless, human antichimeric and human antimouse antibody formation has been minimal, between 0.05% and 1%, respectively. As part of the treatment regimen, predosing with an unlabeled “cold” mAb is used to saturate normal tissue-antigen sinks that highly express CD20 (ie, the spleen), which allows for improved tumor distribution and decreased toxicity. While radiation-induced secondary malignancies may be a concern with these therapies, no increased incidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been seen. In over 1,000 patients treated with 131I-tositumomab monitored from 2 to 5 years from initial treatment, incidence of treatment-related MDS/AML occurred in 3.5% of prior chemotherapy-treated patients, with no increased incidence in any patients treated with 131I-tositumomab as their initial therapy compared to nonradioisotope therapies. For patients treated with 90Y-ibritumomab tiuxetan, annualized incidence rates of MDS or AML were 0.3% from time of diagnosis and 0.7% from time of radioimmunotherapy. The posttreatment rate is comparable to rates reported after long-term alkylating agents. In summary, radioimmunotherapy is a highly effective first-line therapy for indolent lymphoma as well as in relapsed refractory NHL, with minimal and acceptable toxicity.

Phosphatidylinositol 3-kinase pathway and other small-molecule inhibitors

While significant progress has been made in therapeutic antibodies, perhaps the most rapid advances have been made...
in nonantibody therapeutics, including the development of small-molecule inhibitors that modulate key pathways important in NHL pathogenesis. The phosphatidylinositol 3-kinase (PI3K) pathway is a ubiquitous pathway involving a large number of lipid kinases that play critical roles in cell survival, proliferation, metabolism, and angiogenesis. The PI3K pathway is inappropriately activated in many cancers, including NHL, whereby activation is critical for tumor progression and resistance to antitumor drugs. Within the PI3K pathway, activation of PI3K and its downstream kinases AKT, mammalian target of rapamycin (mTOR), and bruton tyrosine kinase (BTK) has been observed with high frequency in multiple NHL subtypes, most notably in DLBCL and MCL. As a result, there has been wide interest in developing selective inhibitors to these components. The development and clinical outcomes of PI3K, AKT, BTK, and mTOR inhibitors will be specifically reviewed here (Figure 3).

**Phosphatidylinositol 3-kinase inhibitors**

PI3Ks are divided into three subclasses on the basis of structure, regulation, and lipid-substrate specificity, of which mutations in class I PI3Ks often lead to activation in many cancers. Within these subclasses, several different isoforms exist, comprised of four different catalytic p110 subunits (α, β, δ, and γ), with variable expression observed across cell types.

![Figure 3](https://www.dovepress.com/)

**Figure 3** Targeting the PI3K and BTK pathways in NHL. The B-cell receptor-signaling pathway (purple) is initiated through phosphorylation of coreceptors that recruit spleen tyrosine kinase (SYK), which then phosphorylates downstream kinases, including PLCγ, leading to activation of Bruton tyrosine kinase (BTK). BTK then binds phosphatidylinositol (3,4,5)-triphosphate (PIP3), which in turn hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers – inositol triphosphate (IP3) and diacylglycerol (DAG) – that ultimately activate downstream proteins involved in B-cell signaling. In the PI3K pathway (orange), activation of receptor tyrosine kinases (RTKs) through adaptor proteins phosphorylates subunits of PI3K, leading to conversion of PIP2 to PIP3. Phosphorylation of the tumor suppressor PTEN terminates PI3K. Accumulation of PIP3 leads to phosphorylation of AKT, which further activates downstream pathways, including mTOR (through the tuberous sclerosis complex 1/2 (TSC1/2)) and other essential pathways. Therapeutic inhibition of select pathway components that have been investigated in clinical trials for NHL are shown.

**Abbreviations:** 4EBP-1, 4E-binding protein 1; GSK3, glycogen synthase kinase 3; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; MDM2, mouse double minute 2 homolog; P, phosphorylation site; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C gamma; PTEN, phosphatase and tensin homolog; RHEB, Ras homolog enriched in brain; S6K, S6 kinase.
This variable expression has led to the development of pan-
PI3K isoform inhibitors. However, the ubiquitous expression
and function of the multiple PI3K isoforms has also led to
serious concerns about significant off-target toxicity. There-
fore, isoform-specific inhibitors have also been explored. The
PI3K-δ isoform is selectively expressed in hematopoietic cells,
thus creating a novel therapeutic target in B-cell malignancies.
The oral PI3K-δ selective inhibitor CAL-101 (now renamed
GS-1101) is perhaps the furthest developed, demonstrating
selective apoptosis of CLL cells in preclinical models and
clinical activity in indolent NHL subtypes. In phase I studies,
GS-1101 was administered to patients with both refractory
and relapsed indolent (FL, CLL) and aggressive (DLBCL,
MCL) NHL (Table 2). Interim analyses in indolent NHL
showed an ORR of 62%, with mean duration of response not
reached. For aggressive NHL subtypes, the ORR was also 62%
in MCL, with median response duration of 3 months. There
was no response in DLBCL patients. Reversible transaminitis
was the only dose-limiting toxicity reported. Another phase I
trial with relapsed/refractory CLL reported an ORR of 26%,
with 80% having a lymph-node response. Combination
therapy with GS-1101 and rituximab and/or bendamustine
in relapsed/refractory CLL has been investigated in a phase I
trial. A favorable safety profile and lack of overlapping
toxicities was observed. Virtually all patients had lymph-node
reduction, with ORR for all regimens between 78% and 87%.
Additionally, GS-1101 was studied in combination with ofatu-
mumab in relapsed/refractory CLL and achieved higher ORR
and nodal response rates than single-agent therapy. Given
the potent activity of GS-1101, other PI3K inhibitors are being
investigated in NHL as single agents and as a combination
strategy, with phase III studies planned.

**AKT inhibitors**

AKT is a serine/threonine kinase that is directly activated
in response to PI3K, and is the PI3K effector that is most
widely implicated in cancer. Activated AKT phosphorylates
numerous substrates that promote growth, proliferation, and
resistance to apoptosis (Figure 3), of which one immediate
consequence is stimulation of mTOR (a therapeutic target
discussed below). Of the selective AKT inhibitors, perifosine,
an oral AKT inhibitor, has been the most characterized,
with efficacy shown mainly in solid tumors and multiple
myeloma. Results from a phase II trial combining perifosine
and sorafenib (an oral multikinase inhibitor) in relapsed/
refractory NHL, Waldenström’s macroglobulinemia, and
HL achieved a partial response of 22%, with a 4-month
median response duration (Table 2). Of note, the majority
of responders were patients with HL. Further clinical studies
are needed to validate perifosine and other AKT inhibitors
specifically in NHL with phase II trials under way.

**BTK inhibitors**

While AKT is the PI3K effector that is most widely
implicated in cancer, there are several AKT-independent
pathways activated by PI3K, which notably include BTK
(Figure 3). BTK is a member of the Tec family of kinases,
with a well-characterized role in B-cell receptor (BCR)
signaling and B-cell activation. BTK is relatively restricted
to hematopoietic cell types, with knockout studies in mice
and man showing a predominant B-cell function. BTK
mutations in humans give rise to X-linked agammaglobulinemia,
an inherited disorder that leads to severely depressed levels
of immunoglobulin production and absence of B cells.
Because expression and knockout is largely restricted to B
cells, BTK has been a uniquely attractive therapeutic target
for malignancies relying on B-cell signaling. Ibrutinib (PCI-
32765), a selective and irreversible oral small-molecule
BTK inhibitor, is the first of its class investigated in NHL.
In vitro, ibrutinib is selectively cytotoxic to DLBCL cell
lines driven by BCR signaling. The first phase I trial with
ibrutinib in relapsed/refractory NHL was well tolerated, and
showed an ORR of 60% across all histologies. Interestingly,
CLL and MCL patients had a strong response rate (79% and
75%, respectively), while FL and DLBCL patients had a poor
response (23% and 17%, respectively) (Table 2). Additionally,
CLL patients noted rapid shrinkage of lymph nodes and
marked lymphocytosis, which is thought to mark malignant
cell egress from lymph nodes to peripheral blood. Given
the specific high response rates and impressive lymph-node
response, ibrutinib was further studied in CLL. Follow-up
phase Ib/II studies in relapsed/refractory CLL achieved an
ORR of 67%, with only minimal grade 3–4 hematologic
xicity. Ibrutinib was also evaluated in treatment-naïve CLL
patients who were 65 years and older. ORR was 74%, with
10% achieving CR and an estimated 15-month PFS observed
in an impressive 96% of patients. Compared to previously
treated patients, the treatment-naïve patients showed faster
response and higher ORR and CR rates. Given these high
efficacy rates, ibrutinib was studied in combination strate-
gies in phase I/II studies. When ibrutinib was combined with
bendamustine and rituximab, ORR was 93%, with 13% of
patients achieving CR. No dose reductions in ibrutinib were
needed, with only a small fraction of patients requiring dose
reductions of bendamustine. When ibrutinib was combined
with ofatumumab, ORR was 100%. Ibrutinib appears to be well tolerated, with some unique
adverse effects that are mostly platelet-mediated, including
Table 2 Emerging non-antibody therapies in non-Hodgkin’s lymphoma

<table>
<thead>
<tr>
<th>Agent</th>
<th>Drug class</th>
<th>Phase</th>
<th>Patients</th>
<th>Disease</th>
<th>Regimen</th>
<th>Response</th>
<th>Ref</th>
<th>Current use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perifosine</td>
<td>AKT inhibitor</td>
<td>II</td>
<td>40</td>
<td>R/R DLBCL, FL, CLL WM, HL</td>
<td>Perifosine (+-sorafenib if failed PR on perifosine)</td>
<td>PR in combination group 22%, stable disease 42%, PD36%</td>
<td>74</td>
<td>Phase III (non-NHL)</td>
</tr>
<tr>
<td>Pixantrone</td>
<td>Aza-anthracenedione</td>
<td>III</td>
<td>140</td>
<td>Relapsed NHL</td>
<td>Pixantrone vs single agent³</td>
<td>CR 20% vs 5.7%</td>
<td>113</td>
<td>EMA conditional approval (relapsed/refractory NHL) FDA-rejected</td>
</tr>
<tr>
<td>Navitoclax</td>
<td>Bcl-2 inhibitor</td>
<td>I</td>
<td>55</td>
<td>R/R NHL</td>
<td>Navitoclax</td>
<td>ORR 21%, PFS14.9 mo</td>
<td>101</td>
<td>Early phase trials</td>
</tr>
<tr>
<td>Oblimersen</td>
<td>Bcl-2 inhibitor</td>
<td>II/II</td>
<td>43</td>
<td>R/R NHL</td>
<td>Oblimersen-R</td>
<td>ORR 42%, CR 23%</td>
<td>99</td>
<td>Phase III</td>
</tr>
<tr>
<td>Oblimersen</td>
<td>Bcl-2 inhibitor</td>
<td>III</td>
<td>241</td>
<td>R/R CLL</td>
<td>F/C ± OBL</td>
<td>CR: OBL-FC 17%, FC 7%</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>AVL-292</td>
<td>BTK inhibitor</td>
<td>Ib</td>
<td>18</td>
<td>R/R NHL</td>
<td>AVL-2929</td>
<td>Dose escalation ongoing</td>
<td>83</td>
<td>Phase I</td>
</tr>
<tr>
<td>Ibrutinib</td>
<td>BTK inhibitor</td>
<td>I</td>
<td>56</td>
<td>R/R CLL, MCL, FL, DBLCL, MZL</td>
<td>Ibrutinib</td>
<td>ORR: CLL 79%, MCL 75%, FL 23%, DBLCL 17%</td>
<td>77</td>
<td>Fast-track status by FDA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ib/II</td>
<td></td>
<td>Un-treated CLL</td>
<td>Ibrutinib</td>
<td>ORR 74%, CR 10%, 15-mo PFS 96%</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ib/II</td>
<td></td>
<td>R/R CLL</td>
<td>Ibrutinib+BR</td>
<td>ORR 93%, CR 13%, 11-mo PFS 90%</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ib/II</td>
<td></td>
<td>R/R CLL</td>
<td>Ibrutinib+ofatumumab</td>
<td>ORR 100%, CR 4%</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Vorinostat</td>
<td>HDAC inhibitor</td>
<td>II</td>
<td>35</td>
<td>R/R FL, MZL, MCL</td>
<td>Vorinostat</td>
<td>ORR: FL 47%, MZL 22%, MCL 0%, CR: FL 1.5%, MZL 11%, MCL 0%</td>
<td>104</td>
<td>FDA-approved for CTCL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I</td>
<td>29</td>
<td>R/R NHL</td>
<td>Vorinostat+RICE</td>
<td>ORR 70%, CR 28%</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td>Romidepsin</td>
<td>HDAC inhibitor</td>
<td>II</td>
<td>47</td>
<td>R/R PTCL</td>
<td>Romidepsin</td>
<td>ORR 38%, CR 18%</td>
<td>107</td>
<td>FDA-approved for CTCL and PTCL</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>Immunomodulant</td>
<td>II</td>
<td>49</td>
<td>R/R NHL</td>
<td>Lenalidomide</td>
<td>ORR 25%, CR 15%</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II/II</td>
<td></td>
<td>R/R NHL</td>
<td>Lenalidomide</td>
<td>ORR 35%, CR 12%</td>
<td>123</td>
<td>Phase III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I/II</td>
<td></td>
<td>R/R MCL</td>
<td>Lenalidomide+R</td>
<td>ORR 57%, CR 36%, median OS 24 mo</td>
<td>126</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td></td>
<td>R/R DLBCL</td>
<td>Lenalidomide+R</td>
<td>ORR 35%</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Everolimus</td>
<td>mTOR inhibitor</td>
<td>II</td>
<td>77</td>
<td>R/R DLBCL, FL</td>
<td>Everolimus</td>
<td>ORR: DLBCL 30%, MCL 32%, FL 38%</td>
<td>89</td>
<td>FDA/EMEA approval for non-NHL cancers</td>
</tr>
<tr>
<td>Temsirolimus</td>
<td>mTOR inhibitor</td>
<td>II</td>
<td>89</td>
<td>R/R DLBCL, FL, CLL WM</td>
<td>Temsirolimus</td>
<td>ORR: DLBCL 28%, FL 54%, CLL 11%, PFS (mo): DLBCL 2.6, FL 12.7</td>
<td>88</td>
<td>EMEA-approved for MCL; FDA approval for non-NHL cancers</td>
</tr>
<tr>
<td>GS-1101 (CAL-101)</td>
<td>PI3K inhibitor</td>
<td>III</td>
<td>161</td>
<td>R/R MCL</td>
<td>Temsirolimus hi/lo³ vs investigator’s choice</td>
<td>PFS (mo): hi 4.8, lo 3.4, investigator’s choice 1.9</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>22</td>
<td>R/R CLL</td>
<td>Everolimus</td>
<td>Partial response 18%</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>I</td>
<td>51</td>
<td>R/R CLL</td>
<td>GS-1101</td>
<td>ORR: indolent and aggressive NHL 62%</td>
<td>68</td>
<td>Planned phase III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I/II</td>
<td></td>
<td>R/R CLL</td>
<td>GS-1101+ofatumumab</td>
<td>ORR: CAL-101+R 78%, +B 82%, +BR 87%</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>I/II</td>
<td></td>
<td>R/R CLL</td>
<td>GS-1101+ofatumumab</td>
<td>ORR 80%, CR 10%, nodal response 83%</td>
<td>71</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Bortezomib is a proteasome inhibitor that has shown significant clinical activity in early phase trials of CML. Ibrutinib is one of few emerging therapies that have shown significant clinical activity against CLL and MCL, and has been given fast-track status by the FDA for accelerated approval for refractory disease. The success of ibrutinib has also spawned the generation of other BTK inhibitors, including the second-in-class inhibitor AVL-292, which is currently in a phase I study for previously treated NHL.

Table 2 (Continued)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Drug class</th>
<th>Phase</th>
<th>Patients</th>
<th>Disease</th>
<th>Regimen</th>
<th>Response</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortezomib</td>
<td>Proteasome inhibitor</td>
<td>II</td>
<td>155</td>
<td>Prior treated MCL</td>
<td>Bortezomib</td>
<td>ORR 31%; CR 8%</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FDA approval for MCL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Current use</td>
<td></td>
</tr>
<tr>
<td>Fostamatinib</td>
<td>Syk inhibitor</td>
<td>I/II</td>
<td>91</td>
<td>R/R NHL</td>
<td>Fostamatinib</td>
<td>ORR 10%–55% based on subtype</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Notes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Indolent NHL included FL, SLL, and MZL; aggressive NHL included MCL and DLBCL; 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td>high-dose temsirolimus, 175 mg IV weekly × 3 cycles followed by 75 mg weekly; low-dose, 175 mg IV weekly × 3 cycles followed by 25 mg weekly; 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>single agents chosen based on investigator's choice included vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine; select clinical trials are reported for the above nonantibody-based therapies.</td>
</tr>
</tbody>
</table>

Notes: Abbreviations: B, bendamustine; CR, complete response; CTCL, cutaneous T-cell lymphoma; CTX, cyclophosphamide; EMA, European Medicines Agency; F/C, fludarabine/cyclophosphamide; HL, Hodgkin's lymphoma; MM, multiple myeloma; Mo, months; OBL, oblimersen; PD, progressive disease; PFS, progression-free survival; PTCL, peripheral T-cell lymphoma; PR, partial response; R/R, relapsed/refractory; R, rituximab; WM, Waldenström's macroglobulinemia.

echymoses and rare occurrences of intracranial hemorrhage. These effects likely reflect the inhibition of platelet function through a direct effect on BTK. The clinical significance of this platelet inhibition is not completely understood; however, caution in combining ibrutinib with antiplatelet agents or other anticoagulants is warranted.

Nevertheless, ibrutinib has shown impressive clinical activity in early phase trials of CLL. Ibrutinib is one of few emerging therapies that have shown significant clinical activity against CLL and MCL, and has been given fast-track status by the FDA for accelerated approval for refractory disease. The success of ibrutinib has also spawned the generation of other BTK inhibitors, including the second-in-class inhibitor AVL-292, which is currently in a phase I study for previously treated NHL.

mTOR inhibitors

One of the major effectors downstream of AKT is mTOR complex 1, which integrates many cellular inputs, including growth-factor signaling, metabolic state, cell survival, and proliferation (Figure 3). The mTOR complex has been therapeutically targeted by rapamycin derivatives, compounds first used in immunosuppression regimens and later in cancer. While rapamycin has been studied as an anticancer therapy, its low oral bioavailability and low solubility in aqueous solutions limited its development. This led to the development of temsirolimus, a naturally occurring water-soluble analog of rapamycin with improved bioavailability when administered intravenously. Temsirolimus, an intravenous prodrug that is metabolized to rapamycin, has been the most extensively evaluated in NHL. The efficacy of temsirolimus was first studied in MCL. MCL is differentiated by the expression of translocation t(11;14) leading to deregulated overexpression of cyclin D1, which can be subsequently targeted by rapamycin analogs. A recent phase III study compared high- and low-dose temsirolimus to investigator's choice of prior approved therapy (Table 2). Higher dosing of temsirolimus outperformed both investigator's choice and lower-dose temsirolimus. However, ORR was 22%, with a median PFS of 4.8 months. Nevertheless, temsirolimus is now being included in treatment guidelines as a therapeutic option for relapsed/refractory MCL. Temsirolimus has also been evaluated in other NHL subtypes. In a large phase II trial, temsirolimus was evaluated in non-MCL NHL. In DLBCL, ORR was 28.1%, including 12.5% achieving CR, but with a median PFS of only 2.6 months. In contrast, 53.8% of FL patients responded, including 25.6% achieving CR, which led to a median PFS of 12.7 months. In CLL and other non-FL indolent lymphomas, only 11% of patients responded.
As an alternative to temsirolimus, everolimus, an oral rapamycin analog, has also been evaluated in multiple NHL subtypes. The most recent phase II trial in DLBCL, MCL, and FL achieved an ORR of 30%, with no major differences between the subtypes (Table 2). In CLL, a separate phase II trial achieved a partial response of 18%.

With respect to toxicities, both temsirolimus and everolimus have similar profiles, with cytopenias being most common and pneumonitis being a concern in patients with a prior history of parenchymal lung disease. While both temsirolimus and everolimus demonstrate clinical response in several NHL subtypes (most notably in MCL), the relatively low response rates as a single agent may argue for these agents to be studied in combination with other therapies. Indeed, early stage trials are in progress for evaluating these rapamycin analogs with chemotherapy and targeted agents, including bendamustine, rituximab, sorafenib, and others.

**Syk inhibitors**

Spleen tyrosine kinase (Syk) is involved in BCR signaling and initiates downstream signaling events after activation of the B-cell receptor (Figure 3). Syk expression and activity levels have been observed in various subtypes of NHL compared to normal B-cell counterparts. Fostamatinib disodium is an oral tyrosine kinase inhibitor whose active metabolite, R406, inhibits Syk at achievable plasma and intracellular concentrations. In a recent phase I/II study, relapsed/refractory NHL of various subtypes (DLBCL, FL, MCL, SLL/CLL) was treated with fostamatinib (Table 2).

Of the various NHL subtypes, ORR ranged between 10% (for FL) up to 55% for SLL/CLL. Neutropenia was the most frequently observed adverse event. Fostamatinib is currently in ongoing phase II trials for NHL.

**Bcl-2 inhibitors**

The Bcl-2 family of proteins consists of proteins involved in pro- (Bax, Bak) and antiapoptotic (Bcl-2, Mcl-1) functions, and regulates the cellular balance between survival and cell death. Given the role of these proteins in cell survival, they have become attractive therapeutic targets in certain cancers. Overexpression of Bcl-2 is common in NHL, and is associated with poor response to therapy and shortened survival. Additionally, overexpression of Bcl-2 has been demonstrated to render NHL subtypes resistant to rituximab-induced apoptosis. These observations and others have led to the development of Bcl-2 inhibitors for the treatment of NHL. Oblimersen is a Bcl-2 antisense molecule that targets and degrades Bcl-2 mRNA. In phase I trials in NHL, oblimersen had limited efficacy, but was generally well tolerated, with myelosuppression observed as the most prevalent adverse event. When combined with rituximab, oblimersen achieved better response rates, with an ORR of 42% and a CR of 23% (Table 2). In the latest phase III trial, relapsed/refractory CLL patients were randomized to fludarabine/cyclophosphamide with or without oblimersen. The oblimersen group demonstrated superior ORR and 5-year median OS. Despite these results, the FDA is requiring a confirmatory trial prior to approval.

Navitoclax (ABT-263) is an orally bioavailable, high-affinity small molecule that inhibits the antiapoptotic activities of Bcl-2 and Bcl-XL. A phase I study in relapsed/refractory NHL achieved an ORR of 21.7% with a median PFS of 14.9 months (Table 2). When combined with rituximab, navitoclax achieved an ORR of 67% with a CR of 33% in a small cohort of relapsed/refractory NHL patients. Significant toxicities included thrombocytopenia and lymphopenia, of which dose-limiting toxicities occurred, cautioning that unacceptable hematologic toxicities may occur with this drug.

**HDAC inhibitors**

Histone deacetylases (HDACs) are a class of enzymes that modify histones through acetylation, leading to changes in DNA expression. Reversible acetylation of proteins represents one of the most abundant posttranslational modifications in cells, and is achieved in great part by HDACs. Aberrant protein acetylation and abnormal expression of HDACs have been associated with human cancers. Increased expression of HDACs has been associated with poor prognosis, tumor invasion, and proliferative index in multiple cancer types. Thus, HDAC inhibitors (HDACis) have emerged as a novel anticancer drug class of great interest, and have shown preclinical and clinical efficacy. While HDACis are effective antiproliferative agents, the exact antineoplastic mechanisms are still unclear. They have been shown to mediate cell death through several pathways, including induction of cell-growth arrest and apoptosis, upregulation of tumor-suppressor genes, alteration of DNA repair and mitosis, induction of protein-folding response, and inhibition of angiogenesis. Currently, two HDACis, vorinostat and romidepsin, are clinically approved for the treatment of malignancies, specifically T-cell lymphomas. Clinical outcomes of vorinostat and romidepsin will be reviewed here. However, multiple HDACis are in clinical trials for other malignancies.
Vorinostat

Vorinostat is an orally bioavailable HDACi with activity against class I and II deacetylases. While it is approved for CTCL, vorinostat has also been shown to have efficacy in other types of lymphoma. A phase II trial of patients with relapsed/refractory FL, MZL, and MCL treated with vorinostat achieved an ORR of 29% and CR of 14.5% (Table 2).\(^\text{104}\) Notably, response rates were significantly higher within FL patients, while no MCL patients responded to the study drug. Thus, vorinostat may have particular efficacy against FL. The median PFS was 15.6 months for FL, 5.9 months for MCL, and 18.8 months for MZL patients. Vorinostat was generally well tolerated, with the most common adverse events being cytopenias and fatigue. Given these results, vorinostat was investigated as a possible adjunct to standard salvage regimens in relapsed aggressive lymphomas as a novel therapeutic option in treating patients who could not receive dose escalation of traditional cytotoxic agents due to increased toxicity. In a phase I trial, vorinostat was added to rituximab + ICE (RICE) in relapsed and refractory NHL.\(^\text{105}\) Results were favorable, with the combination achieving a 70% ORR and a CR in 28% of patients. Results were particularly encouraging in DLBCL previously treated with rituximab, as response rates were 67% with vorinostat + RICE compared to 51% in rituximab-treated DLBCL patients treated with either RICE or rituximab + dexamethasone + cytarabine + cisplatin alone.\(^\text{106}\) Toxicities with the vorinostat combination regimen were comparable to RICE alone, with the exception of more frequent gastrointestinal toxicity and associated electrolyte abnormalities. While vorinostat has shown modest efficacy as a single agent, its therapeutic advantage lies in a combination strategy, given its mild toxicity profile and enhancement of chemotherapeutic efficacy.

Romidepsin

Romidepsin is a bicyclic HDACi that is approved for CTCL as well as PTCL, and has been mostly investigated in T-cell lymphomas. In a phase II trial of patients with relapsed/refractory PTCL, romidepsin achieved an ORR of 38% and a CR of 17%, with a median duration of response of 8.9 months (Table 2).\(^\text{107}\) Common toxicities included thrombocytopenia, granulocytopenia, nausea, and fatigue. However, romidepsin was generally well tolerated, with no dose-limiting toxicities. A larger phase II trial in relapsed/refractory PTCL with romidepsin as a single agent showed similar ORR and CR rates, with no significant dose-limiting toxicities.

Novel chemotherapies

Pixantrone dimaleate

While the anthracycline-containing regimen R-CHOP is the cornerstone of first-line therapy for several NHL subtypes, anthracyclines have limited use in salvage regimens because of progressive dose-dependent cardiotoxicity that leads to progressive congestive heart failure.\(^\text{108}\) Pixantrone dimaleate (pixantrone) is an aza-anthracenedione anthracycline derivative that was synthesized approximately 20 years ago as an agent that provides similar antitumor properties to the anthracyclines, though with reduced cardiotoxicity. Because of structural modifications, pixantrone is less likely to generate reactive oxygen species or form alcohol metabolites, both of which are implicated in anthracycline-induced cardiotoxicity.\(^\text{109,110}\) Preclinical studies demonstrated markedly reduced cardiotoxicity with pixantrone when compared with doxorubicin or its analog mitoxantrone.\(^\text{111}\) In a phase I study in advanced or refractory NHL, pixantrone was tolerable at doses associated with antitumor activity, with grade 4 neutropenia as the sole dose-limiting toxicity.\(^\text{112}\) As a result, pixantrone was purposed as a therapy for NHL patients who had progressed or relapsed after anthracycline-containing treatment regimens. Subsequently, a phase III study was conducted to evaluate pixantrone as a single agent compared to the investigators’ choice of single-agent chemotherapies in NHL patients who had relapsed after two or more prior chemotherapy regimens (one of which had contained an anthracycline) (Table 2).\(^\text{113}\) Importantly, a significant percentage of patients had not been previously treated with rituximab given its lack of availability at that time. Pixantrone-treated patients had a higher CR rate compared with the control group (20% vs 5.7%, respectively). Patients in the pixantrone group also experienced higher rates of neutropenia compared to controls (41.2% vs 19.4%, respectively); however, this frequency was similar to prior anthracycline-based regimens. Of note, a higher frequency of cardiac adverse events was observed in the pixantrone group, which were mostly asymptomatic grade 1 and 2 declines in left ventricular ejection fraction with no evidence of dose-dependent cardiac toxicity. This observation may have been partially due to randomization effects, as five patients in the pixantrone group had histories of congestive heart failure or cardiomyopathy compared to none in the treatment group. Given these mixed results, the utility of pixantrone has been called into question. In 2010, the FDA denied pixantrone approval due to excessive neutropenia and cardiac toxicity as well as a lack of CR in the eight patients treated in the US part of the phase III trial. Despite the FDA’s rejection, the European Medicines Agency
granted drug approval in 2012 for NHL on the condition that pixantrone be further studied in patients who have received rituximab previously. While cardiotoxicity needs to be further investigated, pixantrone may represent an attractive single-agent therapy for refractory NHL.

Bortezomib
The proteasome is a protein complex that is chiefly involved in protein degradation, and represents another avenue for anticancer targeting. Proteasome inhibition has been shown to induce cell-cycle arrest and apoptosis, change cell-surface adhesion markers, and chemosensitize cells, leading to its development as a novel chemotherapy.114

Bortezomib, a proteasome inhibitor, has had particular success in the treatment of hematologic malignancies. It is FDA-approved for multiple myeloma and for MCL patients who have received at least one prior therapy. Bortezomib’s activity in NHL may be in part due to inhibition of the nuclear factor-κB signaling pathway, which is associated with Bcl-2 overexpression as well as activity on p53, which is commonly mutated in select NHL subtypes.114 Bortezomib in combination with rituximab or chemotherapy has been active and generally well tolerated in early phase trials in MCL, FL, and other subtypes of NHL.115–118 In MCL, patients receiving at least one prior therapy were treated with single-agent bortezomib, achieving an ORR of 31% and an 8% CR rate (Table 2).119 This multicenter phase II trial led to the FDA approval of bortezomib for the treatment of MCL patients with at least one prior therapy. Two phase III trials investigated bortezomib with rituximab vs rituximab alone for the treatment of relapsed, rituximab-sensitive/nàïve FL patients. Median PFS and ORR were higher in the bortezomib and rituximab group compared to rituximab alone.120,121 Regarding toxicity, common adverse events included neurologic complications and constipation, with peripheral neuropathies the most common event leading to discontinuation. Currently, bortezomib is a utilized second-line therapy for many MCL patients.

Lenalidomide
In contrast to other chemotherapies, lenalidomide is an immunomodulatory agent with several mechanisms of action, including direct antitumor effects, antiangiogenic properties, stimulation of immune effector cells, including cytotoxic T and natural killer cells, and modulation of the tumor microenvironment.122 Lenalidomide was first investigated in multiple myeloma and MDS, leading to FDA approval for both diseases. Lenalidomide has now been studied in NHL, with early phase trials demonstrating benefit in certain NHL subtypes. Phase II trials in aggressive relapsed/refractory NHL demonstrated an ORR of 35% for all subtypes, with CR rates between 12% and 13%.123,124 ORR was higher in patients with MCL and FL compared to DLBCL.122 Significant toxicities were hematologic, with treatment-related cytopenias leading to dose reduction. Other toxicities included increased risk of thrombosis, hepatotoxicity, and teratogenicity. In addition to monotherapy, lenalidomide has also been studied in combination with rituximab in pretreated elderly DLBCL patients.125 ORR was 35%, with 35% 1-year disease-free survival. In MCL, lenalidomide in combination with rituximab yielded an ORR of 57%, with 36% of patients achieving CR.126 Given the observed activity in refractory patients and relatively well-tolerated toxicity profile, lenalidomide is currently being investigated in newly diagnosed patients who are not candidates for high-dose chemotherapy.127

Conclusion
Relapsed and refractory disease continues to represent the most significant challenge in treating NHL. While rituximab has markedly improved the prognosis of NHL, a significant number of patients are still refractory to rituximab-based therapies. Multiple therapeutic options exist for refractory disease, but the prognosis remains poor. However, in the last decade, several new classes of therapies have shown promise in improving the course of refractory disease. Antibody-based therapies have evolved considerably since the use of rituximab, with multiple next-generation anti-CD20 antibodies, antibody conjugates, and bispecific antibodies demonstrating significant efficacy. In addition, small-molecule inhibitors of PI3K and BTK, including GS-101 and ibrutinib, respectively, have demonstrated remarkable results in relapsed/refractory CLL and MCL, and are anticipated to gain FDA approval within the next year. The future of NHL therapy will continue to rely on the targeting of lymphoma-specific pathways through novel therapeutic approaches.

Disclosure
The author reports no conflicts of interest in this work.

References


Cancer Management and Research 2013:5


Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The journal welcomes original research, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion & commentary, case reports & extended reports. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.